Romiplostin may revert the thrombocytopenia in graft-versus-host disease

Hematology

Volumn 16, Issue 2, 2011, Pages 108-109

  Ruiz Delgado, Guillermo J ^a,c   Lutz Presno, Julia ^b,c   Ruiz Argüelles, Guillermo J ^a,b,c  

^a Clinical Laboratories of Puebla of Bioequivalence   (Mexico)

^b CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^c Escuela de Ciencias Económico Administrativas Universidad Popular Autónoma Del Estado de Puebla   (Mexico)

Author keywords

Graft versus host disease; GVHD; Romiplostin; Thrombocytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; PREDNISONE; ROMIPLOSTIM;

ALLOGRAFT; ARTICLE; B CELL LEUKEMIA; CASE REPORT; CHILD; FEMALE; GRAFT VERSUS HOST REACTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; LEUKEMIA RELAPSE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACUTE DISEASE; CHILD; FEMALE; GRAFT VS HOST DISEASE; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 79952689335     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X12940641877885     Document Type: Article

References (10)

1. Stasi R, Bosworth J, Rhodes E, Shannon MS,Willis F, Gordon-Smith EC. Thrombopoietic agents. Blood Rev 2010;24:179-90.
2. de la Cruz-Vicente F, Alonso-Rosa D, Urbano-Ispizua A. Empleo del romiplostin como agente trombopoyético en la púrpura trombocitopénica inmune. Rev Hematol Méx 2010;11:101-4.
3. Ruiz-Argüelles GJ, Ruiz-Delgado GJ. Enfermedad de injerto contra huésped. Rev Hematol Méx 2010;11(Suppl. 1):31-2.
4. Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft-versus-host disease. Immunol Alergy Clin North Am 2010;30:75-101.
5. Sohn SK, Kim DH, Kim JG, Lee NY, Suh JS, Lee KS, et al. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. Bone Marrow Transplant 2004;34:63-8. (Pubitemid 39022959)
6. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, Jaime-Pérez JC, López-Martínez B, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant 2003;9:157-61.
7. Ruiz-Argüelles GJ, Fernández-Lara D, Estrada-Gómez R, Manzano C, Ruiz-Delgado GJ, Pérez-Romano B, et al. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance. Lab Hematol 2007;13:22-6. (Pubitemid 46578459)
8. Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010;150:9-20.
9. Newland A. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. Eur J Haematol Suppl 2009;(71):20-5.
10. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, et al. Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;116:3163-70.